Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Drops By 5.0%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 47,200 shares, a decrease of 5.0% from the July 31st total of 49,700 shares. Based on an average daily volume of 45,300 shares, the days-to-cover ratio is currently 1.0 days. Approximately 3.6% of the company’s shares are sold short.

Avenue Therapeutics Trading Up 0.8 %

Avenue Therapeutics stock opened at $2.54 on Tuesday. The company has a 50-day moving average price of $3.01 and a 200 day moving average price of $6.15. Avenue Therapeutics has a 12-month low of $2.25 and a 12-month high of $64.27. The stock has a market cap of $3.63 million, a P/E ratio of -0.32 and a beta of -0.19.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings results on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($5.38).

Institutional Investors Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned about 7.97% of Avenue Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 17.34% of the company’s stock.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.